Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms-Reference-Cited by-同舟云学术

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

Published:2017-03-15 Issue:4 Volume:10 Page:30
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Fani Melpomeni,Peitl Petra,Velikyan Irina^ORCID

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

http://www.mdpi.com/1424-8247/10/1/30/pdf

Reference133 articles.

1. Molecular Imaging of Neuroendocrine Tumors

2. The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

3. Current and future radiopharmaceuticals in neuroendocrine tumor imaging In Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors;Fani,2017

4. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)

5. 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate;Pharmaceuticals;2024-04-09

2. Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study;Pharmaceuticals;2024-02-22

3. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides;Chemical Reviews;2023-10-05

4. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future;Cancers;2023-10-03

5. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours;European Journal of Nuclear Medicine and Molecular Imaging;2023-09-18